Validity and reliability of seismocardiography for the estimation of cardiorespiratory fitness
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Forlagets udgivne version, 1,15 MB, PDF-dokument
Background: Low cardiorespiratory fitness (ie, peak oxygen consumption [V.O2peak]) is associated with cardiovascular disease and all-cause mortality and is recognized as an important clinical tool in the assessment of patients. Cardiopulmonary exercise test (CPET) is the gold standard procedure for determination of V.O2peak but has methodological challenges as it is time-consuming and requires specialized equipment and trained professionals. Seismofit is a chest-mounted medical device for estimating V.O2peak at rest using seismocardiography. Objective: The purpose of this study was to investigate the validity and reliability of Seismofit V.O2peak estimation in a healthy population. Methods: On 3 separate days, 20 participants (10 women) underwent estimations of V.O2peak with Seismofit (×2) and Polar Fitness Test (PFT) in randomized order and performed a graded CPET on a cycle ergometer with continuous pulmonary gas exchange measurements. Results: Seismofit V.O2peak showed a significant bias of –3.1 ± 2.4 mL·min–1·kg–1 (mean ± 95% confidence interval) and 95% limits of agreement (LoA) of ±10.8 mL·min–1·kg–1 compared to CPET. The mean absolute percentage error (MAPE) was 12.0%. Seismofit V.O2peak had a coefficient of variation of 4.5% ± 1.3% and an intraclass correlation coefficient of 0.95 between test days and a bias of 0.0 ± 0.4 mL·min–1·kg–1 with 95% LoA of ±1.6 mL·min–1·kg–1 in test–retest. In addition, Seismofit showed a 2.4 mL·min–1·kg–1 smaller difference in 95% LoA than PFT compared to CPET. Conclusion: The Seismofit is highly reliable in its estimation of V.O2peak. However, based on the measurement error and MAPE >10%, the Seismofit V.O2peak estimation model needs further improvement to be considered for use in clinical settings.
|Cardiovascular Digital Health Journal
|Udgivet - 2023
All participants are thanked for their commitment and participation in the study. VentriJect Aps are thanked for providing the equipment for performing the V.O2peak estimation. This work was financially supported by VentriJect Aps. VentriJect Aps support two-thirds of Dr Mikkel Hansen's scholarship. Dr Samuel Emil Schmidt and Dr Kasper Sørensen hold shares in VentriJect Aps. Dr Schmidt works part-time as Chief Scientific Officer and Dr Sørensen full-time as Head of Software at VentriJect Aps. There was no restriction on publication. Declaration of Generative AI and AI-assisted Technologies in the writing process: No generative AI or AI-assisted technologies have been used in the preparation of this work. All authors attest they meet the current ICMJE criteria for authorship. All patients provided written consent. The study conforms to the Helsinki Declaration and was approved by the Science Ethical Committee of the Greater Region of Copenhagen, Denmark (H-19081375). All data that were used in the current study are available upon reasonable request. The estimated and measured V.O2peak values on the 3 test days from all the participants are given in Supplemental Table 3.
This work was financially supported by VentriJect Aps .
© 2023 Heart Rhythm Society